Gene Veritas Blog

Pharma giant Roche is gearing up for the pivotal Phase 3 clinical trial of IONIS-HTTRx (RG6042) the gene-silencing drug shown to dramatically reduce the amount of the toxic protein implicated in Huntington’s disease. Read More here.